AsymBio
A Connected Biologics Path to Commercialization
Rui Yang, CEO
Top Integrated Biologics CDMO Companies in APAC 2026
Integrated biologics CDMO companies help life sciences organizations develop and manufacture biologic therapies through outsourced support. With a focus on process development, quality control, regulatory readiness and manufacturing scalability, they support stronger therapeutic pipelines and more reliable production.
Solutions
For pharma and biotech companies, choosing the right biologics CDMO comes down to one fundamental question: can a single CDMO partner support a drug program from early development through commercialization while ensuring continuity?
State of Industry
Integrated Biologics CDMOs: Building End-to-End Manufacturing Strength across APAC
Integrated biologics CDMOs are becoming important partners across the Asia-Pacific (APAC) life sciences sector as drug developers seek faster, more coordinated routes from early development to commercial manufacturing. These providers combine cell line development, process design, analytical services, clinical production, fill-finish support and large-scale manufacturing within connected operating models.
Deep Dive
Selecting an Integrated Biologics CDMO for Development Continuity
Biologics programs can lose time at the handoffs between early development and manufacturing. A cell line may be technically sound yet create downstream purification burdens, while formulation choices made too late can complicate scale-up, stability work, technology transfer and filing preparation. For executives choosing an integrated biologics CDMO, the central question is not how many services sit on one menu. It is whether decisions made at one stage remain visible to the teams responsible for the next stage.
Leadership Perspective
FUJIFILM Diosynth Biotechnologies
Modular approach for Large Scale Cell Culture CDMO facilities
Jacob Gronnegaard, Director Automation
The market demand for large-scale cell culture production capacity is growing, and FUJIFILM Diosynth Biotechnologies is meeting the market demand by expanding its production capacity with new drug substances, drug products, and finished goods facilities. And we are deploying a modular approach specifically for drug substance manufacturing.
Integrated Biologics CDMO Companies in APAC Info
Q1
What Do Top Integrated Biologics CDMO Providers Typically Cover?
Top Integrated Biologics CDMO providers support pharmaceutical and biotechnology programs across multiple stages of development and manufacturing. Their scope can include developability assessment, cell line development, process development, analytical work, technology transfer, clinical manufacturing, commercial production and regulatory support. An integrated model connects these activities so technical decisions made early can remain aligned with later manufacturing requirements. Depending on the program, services may cover conventional antibodies, recombinant proteins, bispecific or multispecific antibodies, antibody-drug conjugates and other complex biologic modalities.
Q2
Why Is Demand Growing for Integrated Biologics CDMO Services?
Demand is being shaped by the increasing complexity of biologic pipelines, the expansion of advanced modalities and the need to move promising candidates efficiently from laboratory development toward clinical and commercial stages. Top Integrated Biologics CDMO services can give drug developers access to specialized scientific capabilities and manufacturing infrastructure without requiring every function to be built internally. The ability to coordinate development, scale-up, quality systems and regulatory requirements is particularly relevant when programs involve multiple technologies or geographically distributed development activities.
Q3
Which Organization Did Life Sciences Review Recognize as an Integrated Biologics CDMO in 2026?
Life Sciences Review recognized AsymBio as the Integrated Biologics CDMO Company of the Year in APAC 2026. The recognition reflects AsymBio’s role in supporting biologics programs through an integrated development and manufacturing model. Its stated capabilities span early developability assessment, technology transfer, manufacturing and regulatory filing support. The company works across conventional antibodies and proteins as well as bispecific and trispecific antibodies, advanced antibody-drug conjugates and other conjugated modalities.
Q4
What Should Drug Developers Evaluate When Choosing an Integrated Biologics CDMO?
Evaluation should extend beyond individual services to how effectively a CDMO connects scientific development with manufacturing execution. Top Integrated Biologics CDMO providers should be assessed for modality expertise, process-development capabilities, manufacturing scale, analytical support, quality systems, regulatory readiness and technology-transfer processes. Developers should also consider capacity at different stages, communication practices, data ownership, intellectual-property protections and the ability to manage changes as a program advances. Clear alignment between development strategy and manufacturing requirements can reduce avoidable delays, technical rework and scale-up challenges.
Q5
How Do Top Integrated Biologics CDMO Platforms Use Technology and Expertise?
Technology increasingly connects upstream and downstream development, formulation, conjugation and manufacturing decisions. Top Integrated Biologics CDMO platforms may use specialized cell-line technologies, process-development systems, conjugation tools, analytical workflows and data-driven methods to improve process understanding. Expertise remains equally important because biologics require careful control of product quality, process consistency and manufacturability. Strong integration allows information generated at one development stage to inform decisions at another rather than treating each activity as an isolated service.
Q6
Why Was AsymBio Recognized by Life Sciences Review for 2026?
AsymBio was recognized for several key strengths. Its integrated model supports programs from early development through manufacturing and regulatory support. The company’s technology platforms link cell-line development, upstream and downstream processing, payload-linker development, conjugation, and drug product development. AsymBio runs manufacturing facilities in Shanghai that serve clinical and commercial needs at different scales. Its quality framework meets the standards of major regulatory authorities, and the company has experience with over 1,000 early-development and preclinical projects and more than 100 IND-stage programs.
